Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1980 Jul;10(1):5–21. doi: 10.1111/j.1365-2125.1980.tb00497.x

Neuroendocrine markers of CNS drug effects.

E C Johnstone, I N Ferrier
PMCID: PMC1430015  PMID: 6104974

Full text

PDF
14

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Annunziato L. Regulation of the tuberoinfundibular and nigrostriatal systems. Evidence for different kinds of dopaminergic neurons in the brain. Neuroendocrinology. 1979;29(1):66–76. doi: 10.1159/000122906. [DOI] [PubMed] [Google Scholar]
  2. Arendash G. W., Gallo R. V. Apomorphine-induced inhibition of episodic LH release in ovariectomized rats with complete hypothalamic deafferentation. Proc Soc Exp Biol Med. 1978 Oct;159(1):121–125. doi: 10.3181/00379727-159-40296. [DOI] [PubMed] [Google Scholar]
  3. Baastrup P. C., Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry. 1967 Feb;16(2):162–172. doi: 10.1001/archpsyc.1967.01730200030005. [DOI] [PubMed] [Google Scholar]
  4. Barlow S. M., Knight A. F., Sullivan F. M. Plasma corticosterone responses to stress following chronic oral administration of diazepam in the rat. J Pharm Pharmacol. 1979 Jan;31(1):23–26. doi: 10.1111/j.2042-7158.1979.tb13415.x. [DOI] [PubMed] [Google Scholar]
  5. Beg A. A., Varma V. K., Dash R. J. Effect of chlorpromazine on human growth hormone. Am J Psychiatry. 1979 Jul;136(7):914–917. doi: 10.1176/ajp.136.7.914. [DOI] [PubMed] [Google Scholar]
  6. Ben-Jonathan N., Oliver C., Weiner H. J., Mical R. S., Porter J. C. Dopamine in hypophysial portal plasma of the rat during the estrous cycle and throughout pregnancy. Endocrinology. 1977 Feb;100(2):452–458. doi: 10.1210/endo-100-2-452. [DOI] [PubMed] [Google Scholar]
  7. Bennett G. W., Edwardson J. A., Holland D., Jeffcoate S. L., White N. Release of immunoreactive luteinising hormone-releasing hormone and thyrotrophin-releasing hormone from hypothalamus. Nature. 1975 Sep 25;257(5524):323–325. doi: 10.1038/257323a0. [DOI] [PubMed] [Google Scholar]
  8. Benowitz N. L., Jones R. T., Lerner C. B. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man. J Clin Endocrinol Metab. 1976 May;42(5):938–941. doi: 10.1210/jcem-42-5-938. [DOI] [PubMed] [Google Scholar]
  9. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. doi: 10.1016/0022-510x(73)90175-5. [DOI] [PubMed] [Google Scholar]
  10. Berson S. A., Yalow R. S. General principles of radioimmunoassay. Clin Chim Acta. 1968 Sep;22(1):51–69. doi: 10.1016/0009-8981(68)90247-7. [DOI] [PubMed] [Google Scholar]
  11. Besser G. M., Parke L., Edwards C. R., Forsyth I. A., McNeilly A. S. Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Br Med J. 1972 Sep 16;3(5828):669–672. doi: 10.1136/bmj.3.5828.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Besses G. S., Burrow G. N., Spaulding S. W., Donabedian R. K. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J Clin Endocrinol Metab. 1975 Nov;41(5):985–988. doi: 10.1210/jcem-41-5-985. [DOI] [PubMed] [Google Scholar]
  13. Beumont P. J., Corker C. S., Friesen H. G., Kolakowska T., Mandelbrote M., Marshall J., Murray M. A., Wiles D. H. The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women. Br J Psychiatry. 1974 May;124(0):420–430. doi: 10.1192/bjp.124.5.420. [DOI] [PubMed] [Google Scholar]
  14. Bird E. D., Iversen L. L. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain. 1974 Sep;97(3):457–472. doi: 10.1093/brain/97.1.457. [DOI] [PubMed] [Google Scholar]
  15. Birge C. A., Jacobs L. S., Hammer C. T., Daughaday W. H. Catecholamine inhibition of prolactin secretion by isolated rat adenohypophyses. Endocrinology. 1970 Jan;86(1):120–130. doi: 10.1210/endo-86-1-120. [DOI] [PubMed] [Google Scholar]
  16. Bivens C. H., Lebovitz H. E., Feldman J. M. Inhibition of hypoglycemia-induced growth hormone secretion by the serotonin antagonists cyproheptadine and methysergide. N Engl J Med. 1973 Aug 2;289(5):236–239. doi: 10.1056/NEJM197308022890503. [DOI] [PubMed] [Google Scholar]
  17. Blackwell B. Psychotropic drugs in use today. The role of diazepam in medical practice. JAMA. 1973 Sep 24;225(13):1637–1641. [PubMed] [Google Scholar]
  18. Brambilla F., Guerrini A., Guastalla A., Rovere C., Riggi F. Neuroendocrine effects of haloperidol therapy in chronic schizophrenia. Psychopharmacologia. 1975 Oct 14;44(1):17–22. doi: 10.1007/BF00421177. [DOI] [PubMed] [Google Scholar]
  19. Brambilla F., Resele L., De Maio D., Nobile P. Gonadotropin response to synthetic gonadotropin hormone-releasing hormone (GnRH) in heroin addicts. Am J Psychiatry. 1979 Mar;136(3):314–317. doi: 10.1176/ajp.136.3.314. [DOI] [PubMed] [Google Scholar]
  20. Brown G. M., Seeman P., Lee T. Dopamine/neuroleptic receptors in basal hypothalamus and pituitary. Endocrinology. 1976 Nov;99(5):1407–1406. doi: 10.1210/endo-99-5-1407. [DOI] [PubMed] [Google Scholar]
  21. Bruni J. F., Van Vugt D., Marshall S., Meites J. Effects of naloxone, morphine and methionine enkephalin on serum prolactin, luteinizing hormone, follicle stimulating hormone, thyroid stimulating hormone and growth hormone. Life Sci. 1977 Aug 1;21(3):461–466. doi: 10.1016/0024-3205(77)90528-8. [DOI] [PubMed] [Google Scholar]
  22. Burrow G. N., May P. B., Spaulding S. W., Donabedian R. K. TRH and dopamine interactions affecting pituitary hormones secretion. J Clin Endocrinol Metab. 1977 Jul;45(1):65–72. doi: 10.1210/jcem-45-1-65. [DOI] [PubMed] [Google Scholar]
  23. CHRISTY N. P., LONGSON D., HORWITZ W. A., KNIGHT M. M. Inhibitory effect of chlorpromazine upon the adrenal cortical response to insulin hypoglycemia in man. J Clin Invest. 1957 Apr;36(4):543–549. doi: 10.1172/JCI103452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Camanni F., Massara F., Belforte L., Molinatti G. M. Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine. J Clin Endocrinol Metab. 1975 Mar;40(3):363–366. doi: 10.1210/jcem-40-3-363. [DOI] [PubMed] [Google Scholar]
  25. Camanni F., Massara F., Belforte L., Rosatello A., Molinatti G. M. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. J Clin Endocrinol Metab. 1977 Mar;44(3):465–473. doi: 10.1210/jcem-44-3-465. [DOI] [PubMed] [Google Scholar]
  26. Caraceni T., Panerai A. E., Paratl E. A., Cocchi D., Müller E. E. Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. J Clin Endocrinol Metab. 1977 May;44(5):870–875. doi: 10.1210/jcem-44-5-870. [DOI] [PubMed] [Google Scholar]
  27. Chalmers R. J., Bennie E. H., Johnson R. H., Kinnell H. G. The growth hormone response to insulin induced hypoglycaemia in alcoholics. Psychol Med. 1977 Nov;7(4):607–611. doi: 10.1017/s0033291700006243. [DOI] [PubMed] [Google Scholar]
  28. Chalmers R. J., Johnson R. H., Keogh H. J., Nanda R. N. Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea. J Neurol Neurosurg Psychiatry. 1978 Feb;41(2):135–139. doi: 10.1136/jnnp.41.2.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Checkley S. A. Corticosteroid and growth hormone responses to methylamphetamine in depressive illness. Psychol Med. 1979 Feb;9(1):107–115. doi: 10.1017/s0033291700021619. [DOI] [PubMed] [Google Scholar]
  30. Checkley S. A. Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness. Psychol Med. 1980 Feb;10(1):35–53. doi: 10.1017/s0033291700039593. [DOI] [PubMed] [Google Scholar]
  31. Chihara K., Kato Y., Maeda K., Matsukura S., Imura H. Suppression by cyproheptadine of human growth hormone and cortisol secretion during sleep. J Clin Invest. 1976 Jun;57(6):1393–1402. doi: 10.1172/JCI108408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Cicero T. J., Bell R. D., Wiest W. G., Allison J. H., Polakoski K., Robins E. Function of the male sex organs in heroin and methadone users. N Engl J Med. 1975 Apr 24;292(17):882–887. doi: 10.1056/NEJM197504242921703. [DOI] [PubMed] [Google Scholar]
  33. Cocchi D., Gil-Ad I., Parenti M., Stefanini E., Locatelli V., Müller E. E. Prolactin-releasing effect of a novel anti-dopaminergic drug, domperidone, in the rat. Neuroendocrinology. 1980;30(2):65–69. doi: 10.1159/000122977. [DOI] [PubMed] [Google Scholar]
  34. Coppen A., Ghose K. Peripheral alpha-adrenoreceptor and central dopamine receptor activity in depressive patients. Psychopharmacology (Berl) 1978 Oct 31;59(2):171–177. doi: 10.1007/BF00427753. [DOI] [PubMed] [Google Scholar]
  35. Coppen A., Montgomery S., Peet M., Bailey J., Marks V., Woods P. Thyrotrophin-releasing hormone in the treatment of depression. Lancet. 1974 Aug 24;2(7878):433–434. doi: 10.1016/s0140-6736(74)91817-0. [DOI] [PubMed] [Google Scholar]
  36. Cotes P. M., Crow T. J., Johnstone E. C., Bartlett W., Bourne R. C. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication. Psychol Med. 1978 Nov;8(4):657–665. doi: 10.1017/s0033291700018869. [DOI] [PubMed] [Google Scholar]
  37. Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976 Apr 30;192(4238):481–483. doi: 10.1126/science.3854. [DOI] [PubMed] [Google Scholar]
  38. Cushman P., Jr Plasma testosterone in narcotic addiction. Am J Med. 1973 Oct;55(3):452–458. doi: 10.1016/0002-9343(73)90202-7. [DOI] [PubMed] [Google Scholar]
  39. Delitala G., Wass J. A., Stubbs W. A., Jones A., Williams S., Besser G. M. The effect of lisuride hydrogen maleate, an ergot derivative on anterior pituitary hormone secretion in man. Clin Endocrinol (Oxf) 1979 Jul;11(1):1–9. doi: 10.1111/j.1365-2265.1979.tb03041.x. [DOI] [PubMed] [Google Scholar]
  40. Diefenbach W. P., Carmel P. W., Frantz A. G., Ferin M. Suppression of prolactin secretion by L-dopa in the stalk-sectioned rhesus monkey. J Clin Endocrinol Metab. 1976 Sep;43(3):638–642. doi: 10.1210/jcem-43-3-638. [DOI] [PubMed] [Google Scholar]
  41. Drouva S. V., Gallo R. V. Further evidence for inhibition of episodic luteinizing hormone release in ovariectomized rats by stimulation of dopamine receptors. Endocrinology. 1977 Mar;100(3):792–798. doi: 10.1210/endo-100-3-792. [DOI] [PubMed] [Google Scholar]
  42. Dunne M. J., Walker J., Cowden E. A., Ratcliffe J. G. Nomifensine test for investigation of hyperprolactinaemia. Lancet. 1979 Dec 8;2(8154):1243–1243. doi: 10.1016/s0140-6736(79)92360-2. [DOI] [PubMed] [Google Scholar]
  43. Ettigi P. G., Brown G. M. Psychoneuroendocrinology of affective disorder: an overview. Am J Psychiatry. 1977 May;134(5):493–501. doi: 10.1176/ajp.134.5.493. [DOI] [PubMed] [Google Scholar]
  44. Ettigi P., Nair N. P., Lal S., Cervantes P., Guyda H. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. J Neurol Neurosurg Psychiatry. 1976 Sep;39(9):870–876. doi: 10.1136/jnnp.39.9.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Forrest J. N., Jr, Cohen A. D., Torretti J., Himmelhoch J. M., Epstein F. H. On the mechanism of lithium-induced diabetes insipidus in man and the rat. J Clin Invest. 1974 Apr;53(4):1115–1123. doi: 10.1172/JCI107649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Friend W. C., Brown G. M., Jawahir G., Lee T., Seeman P. Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum. Am J Psychiatry. 1978 Jul;135(7):839–841. doi: 10.1176/ajp.135.7.839. [DOI] [PubMed] [Google Scholar]
  47. Friesen H., Guyda H., Hwang P., Tyson J. E., Barbeau A. Functional evaluation of prolactin secretion: a guide to therapy. J Clin Invest. 1972 Mar;51(3):706–709. doi: 10.1172/JCI106859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Gallager D. W., Pert A., Bunney W. E., Jr Haloperidol-induced presynaptic dopamine supersensitivity is blocked by chronic lithium. Nature. 1978 May 25;273(5660):309–312. doi: 10.1038/273309a0. [DOI] [PubMed] [Google Scholar]
  49. Gil-Ad I., Topper E., Laron Z. Oral clonidine as a growth hormone stimulation test. Lancet. 1979 Aug 11;2(8137):278–279. doi: 10.1016/s0140-6736(79)90293-9. [DOI] [PubMed] [Google Scholar]
  50. Gold M. S., Pottash A. L., Davies R. K., Ryan N., Sweeney D. R., Martin D. M. Distinguishing unipolar and bipolar depression by thyrotropin release test. Lancet. 1979 Aug 25;2(8139):411–412. doi: 10.1016/s0140-6736(79)90421-5. [DOI] [PubMed] [Google Scholar]
  51. Gold M. S., Redmond D. E., Jr, Donabedian R. K. Prolactin secretion, a measurable central effect of opiate-receptor antagonists. Lancet. 1978 Feb 11;1(8059):323–324. doi: 10.1016/s0140-6736(78)90089-2. [DOI] [PubMed] [Google Scholar]
  52. Gold P. W., Goodwin F. K., Wehr T., Rebar R., Sack R. Growth-hormone and prolactin response to levodopa in affective illness. Lancet. 1976 Dec 11;2(7998):1308–1309. doi: 10.1016/s0140-6736(76)92079-1. [DOI] [PubMed] [Google Scholar]
  53. Gruen P. G., Sachar E. J., Altman N., Langer G., Tabrizi M. A., Halpern F. S. Relation of plasma prolactin to clinical response in schizophrenic patients. Arch Gen Psychiatry. 1978 Oct;35(10):1222–1227. doi: 10.1001/archpsyc.1978.01770340072008. [DOI] [PubMed] [Google Scholar]
  54. Gruen P. H., Sachar E. J., Altman N., Sassin J. Growth hormone responses to hypoglycemia in postmenopausal depressed women. Arch Gen Psychiatry. 1975 Jan;32(1):31–33. doi: 10.1001/archpsyc.1975.01760190033003. [DOI] [PubMed] [Google Scholar]
  55. Gruen P. H., Sachar E. J., Langer G., Altman N., Leifer M., Frantz A., Halpern F. S. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry. 1978 Jan;35(1):108–116. doi: 10.1001/archpsyc.1978.01770250110011. [DOI] [PubMed] [Google Scholar]
  56. Gudelsky G. A., Moore E. K. Differential drug effects on dopamine concentrations and rates of turnover in the median eminence, olfactory tubercle and corpus striatum. J Neural Transm. 1976;38(2):95–105. doi: 10.1007/BF01262968. [DOI] [PubMed] [Google Scholar]
  57. Halmi K. A., Goldberg S. C. Cyproheptadine in anorexia nervosa [proceedings]. Psychopharmacol Bull. 1978 Apr;14(2):31–33. [PubMed] [Google Scholar]
  58. Hanssen T., Heyden T., Sundberg I., Wetterberg L., Eneroth P. Decrease in serum-prolactin after propranolol in schizophrenia. Lancet. 1978 Jan 14;1(8055):101–102. doi: 10.1016/s0140-6736(78)90046-6. [DOI] [PubMed] [Google Scholar]
  59. Hayek A., Crawford J. D. L-DOPA and pituitary hormone secretion. J Clin Endocrinol Metab. 1972 May;34(5):764–766. doi: 10.1210/jcem-34-5-764. [DOI] [PubMed] [Google Scholar]
  60. Healy D. L., Burger H. G. Increased prolactin and thyrotrophin secretion following oral metoclopramide: dose-response relationships. Clin Endocrinol (Oxf) 1977 Sep;7(3):195–201. doi: 10.1111/j.1365-2265.1977.tb01315.x. [DOI] [PubMed] [Google Scholar]
  61. Himsworth R. L., Carmel P. W., Frantz A. G. The location of the chemoreceptor controlling growth hormone secretion during hypoglycemia in primates. Endocrinology. 1972 Jul;91(1):217–226. doi: 10.1210/endo-91-1-217. [DOI] [PubMed] [Google Scholar]
  62. Hollister L. E., Davis K. L., Berger P. A. Pituitary response to thyrotropin-releasing hormone in depression. Arch Gen Psychiatry. 1976 Nov;33(11):1393–1396. doi: 10.1001/archpsyc.1976.01770110121013. [DOI] [PubMed] [Google Scholar]
  63. Idänpän-Heikkilä J., Alhava E., Olkinuora M., Palva I. P. Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol. 1977 Mar 11;11(3):193–198. doi: 10.1007/BF00606409. [DOI] [PubMed] [Google Scholar]
  64. Imura H., Nakai Y., Yoshimi T. Effect of 5-hydroxytryptophan (5-HTP) on growth hormone and ACTH release in man. J Clin Endocrinol Metab. 1973 Jan;36(1):204–206. doi: 10.1210/jcem-36-1-204. [DOI] [PubMed] [Google Scholar]
  65. Janowsky D., Judd L., Huey L., Roitman N., Parker D. Naloxone effects on serum growth hormone and prolactin in man. Psychopharmacology (Berl) 1979 Sep;65(1):95–97. doi: 10.1007/BF00491986. [DOI] [PubMed] [Google Scholar]
  66. Johnstone E. C., Crow T. J., Mashiter K. Anterior pituitary hormone secretion in chronic schizophrenia--an approach to neurohumoral mechanisms. Psychol Med. 1977 May;7(2):223–228. doi: 10.1017/s0033291700029299. [DOI] [PubMed] [Google Scholar]
  67. Jones R. B., Luscombe D. K., Groom G. V. Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J. 1977;53 (Suppl 4):166–171. [PubMed] [Google Scholar]
  68. Kamberi I. A., Mical R. S., Porter J. C. Effect of anterior pituitary perfusion and intraventricular injection of catecholamines on prolactin release. Endocrinology. 1971 Apr;88(4):1012–1020. doi: 10.1210/endo-88-4-1012. [DOI] [PubMed] [Google Scholar]
  69. Kirkegaard C., Norlem N., Lauridsen U. B., Bjorum N., Christiansen C. Protirelin stimulation test and thyroid function during treatment of depression. Arch Gen Psychiatry. 1975 Sep;32(9):1115–1118. doi: 10.1001/archpsyc.1975.01760270047004. [DOI] [PubMed] [Google Scholar]
  70. Kolakowska T., Wiles D. H., McNeilly A. S., Gelder M. G. Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients. Psychol Med. 1975 May;5(2):214–216. doi: 10.1017/s0033291700056488. [DOI] [PubMed] [Google Scholar]
  71. Kolodny R. C., Masters W. H., Kolodner R. M., Toro G. Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med. 1974 Apr 18;290(16):872–874. doi: 10.1056/NEJM197404182901602. [DOI] [PubMed] [Google Scholar]
  72. Koulu M., Lammintausta R., Kangas L., Dahlström S. The effect of methysergide, pimozide, and sodium valproate on the diazepam-stimulated growth hormone secretion in man. J Clin Endocrinol Metab. 1979 Jan;48(1):119–122. doi: 10.1210/jcem-48-1-119. [DOI] [PubMed] [Google Scholar]
  73. Lachelin G. C., Leblanc H., Yen S. S. The inhibitory effect of dopamine agonists on LH release in women. J Clin Endocrinol Metab. 1977 Apr;44(4):728–732. doi: 10.1210/jcem-44-4-728. [DOI] [PubMed] [Google Scholar]
  74. Lal H., Brown W., Drawbaugh R., Hynes M., Brown G. Enhanced prolactin inhibition following chronic treatment with haloperidol and morphine. Life Sci. 1977 Jan 1;20(1):101–105. doi: 10.1016/0024-3205(77)90134-5. [DOI] [PubMed] [Google Scholar]
  75. Lal S., De la Vega C. E., Sourkes T. L., Friesen H. G. Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. J Clin Endocrinol Metab. 1973 Nov;37(5):719–724. doi: 10.1210/jcem-37-5-719. [DOI] [PubMed] [Google Scholar]
  76. Lal S., Guyda H., Bikadoroff S. Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men. J Clin Endocrinol Metab. 1977 Apr;44(4):766–770. doi: 10.1210/jcem-44-4-766. [DOI] [PubMed] [Google Scholar]
  77. Lal S., Martin J. B., De la Vega C. E., Friesen H. G. Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men. Clin Endocrinol (Oxf) 1975 May;4(3):277–285. doi: 10.1111/j.1365-2265.1975.tb01535.x. [DOI] [PubMed] [Google Scholar]
  78. Lal S., Tolis G., Martin S. B., Brown G. M., Guyda H. Effect of clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone in the serum of normal men. J Clin Endocrinol Metab. 1975 Nov;41(5):827–832. doi: 10.1210/jcem-41-5-827. [DOI] [PubMed] [Google Scholar]
  79. Langer G., Heinze G., Reim B., Matussek N. Reduced growth hormone responses to amphetamine in "endogenous" depressive patients: studies in normal, "reactive" and "endogenous" depressive, schizophrenic, and chronic alcoholic subjects. Arch Gen Psychiatry. 1976 Dec;33(12):1471–1475. doi: 10.1001/archpsyc.1976.01770120075007. [DOI] [PubMed] [Google Scholar]
  80. Langer G., Matussek N. Dextro- and L-amphetamine are equipotent in releasing human growth hormone. Psychoneuroendocrinology. 1977 Oct;2(4):379–382. doi: 10.1016/0306-4530(77)90008-7. [DOI] [PubMed] [Google Scholar]
  81. Langer G., Sachar E. J., Gruen P. H., Halpern F. S. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature. 1977 Apr 14;266(5603):639–640. doi: 10.1038/266639a0. [DOI] [PubMed] [Google Scholar]
  82. Langer G., Sachar E. J., Nathan R. S., Tabrizi M. A., Perel J. M., Halpern F. S. Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man. Psychopharmacology (Berl) 1979 Oct;65(2):161–164. doi: 10.1007/BF00433043. [DOI] [PubMed] [Google Scholar]
  83. Langer G., Schönbeck G., Koinig G., Lesch O., Schüssler M., Waldhäusl W. Antidepressant drugs and the hypothalamic-pituitary-thyroid axis. Lancet. 1980 Jan 12;1(8159):100–101. doi: 10.1016/s0140-6736(80)90530-9. [DOI] [PubMed] [Google Scholar]
  84. Lapin I. P., Oxenkrug G. F. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet. 1969 Jan 18;1(7586):132–136. doi: 10.1016/s0140-6736(69)91140-4. [DOI] [PubMed] [Google Scholar]
  85. Lawson D. M., Gala R. R. The influence of adrenergic, dopaminergic, cholinergic and serotoninergic drugs on plasma prolactin levels in ovariectomized, estrogen-treated rats. Endocrinology. 1975 Feb;96(2):313–318. doi: 10.1210/endo-96-2-313. [DOI] [PubMed] [Google Scholar]
  86. Leblanc H., Lachelin G. C., Abu-Fadil S., Yen S. S. Effects of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab. 1976 Sep;43(3):668–674. doi: 10.1210/jcem-43-3-668. [DOI] [PubMed] [Google Scholar]
  87. Leebaw W. F., Lee L. A., Woolf P. D. Dopamine affects basal and augmented pituitary hormone secretion. J Clin Endocrinol Metab. 1978 Sep;47(3):480–487. doi: 10.1210/jcem-47-3-480. [DOI] [PubMed] [Google Scholar]
  88. Leppäluoto J., Männistö P., Ranta T., Linnoila M. Inhibition of mid-cycle gonadotrophin release in healthy women by pimozide and fusaric acid. Acta Endocrinol (Copenh) 1976 Mar;81(3):455–460. doi: 10.1530/acta.0.0810455. [DOI] [PubMed] [Google Scholar]
  89. Lindstedt G., Nilsson L. A., Wålinder J., Skott A., Ohman R. On the prevalence, diagnosis and management of lithium-induced hypothyroidism in psychiatric patients. Br J Psychiatry. 1977 May;130:452–458. doi: 10.1192/bjp.130.5.452. [DOI] [PubMed] [Google Scholar]
  90. Loosen P. T., Prange A. J., Jr, Wilson I. C. TRH (protirelin) in depressed alcoholic men. Behavioral changes and endocrine responses. Arch Gen Psychiatry. 1979 May;36(5):540–547. doi: 10.1001/archpsyc.1979.01780050050005. [DOI] [PubMed] [Google Scholar]
  91. Lucke C., Glick S. M. Experimental modification of the sleep-induced peak of growth hormone secretion. J Clin Endocrinol Metab. 1971 Jun;32(6):729–736. doi: 10.1210/jcem-32-6-729. [DOI] [PubMed] [Google Scholar]
  92. MacLeod R. M., Lehmeyer J. E. Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology. 1974 Apr;94(4):1077–1085. doi: 10.1210/endo-94-4-1077. [DOI] [PubMed] [Google Scholar]
  93. Malarkey W. B., Cyrus J., Paulson G. W. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy. J Clin Endocrinol Metab. 1974 Aug;39(2):229–235. doi: 10.1210/jcem-39-2-229. [DOI] [PubMed] [Google Scholar]
  94. Marcano de Cotte D., De Menezes C. E., Bennett G. W., Edwardson J. A. Dopamine stimulates the degradation of gonadotropin releasing hormone by rat synaptosomes. Nature. 1980 Jan 31;283(5746):487–489. doi: 10.1038/283487a0. [DOI] [PubMed] [Google Scholar]
  95. Martin J. B., Lal S., Tolis G., Friesen H. G. Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin. J Clin Endocrinol Metab. 1974 Jul;39(1):180–182. doi: 10.1210/jcem-39-1-180. [DOI] [PubMed] [Google Scholar]
  96. Martin J. B. Neural regulation of growth hormone secretion. N Engl J Med. 1973 Jun 28;288(26):1384–1393. doi: 10.1056/NEJM197306282882606. [DOI] [PubMed] [Google Scholar]
  97. Masala A., Alagna S., Devilla L., Delitala G., Rovasio P. P. Inhibition of prolactin secretion by nomifensine in man. Clin Endocrinol (Oxf) 1980 Mar;12(3):237–241. doi: 10.1111/j.1365-2265.1980.tb02705.x. [DOI] [PubMed] [Google Scholar]
  98. McNeill T. H., Sladek J. R., Jr Fluorescence-immunocytochemistry: simultaneous localization of catecholamines and gonadotropin-releasing hormone. Science. 1978 Apr 7;200(4337):72–74. doi: 10.1126/science.345442. [DOI] [PubMed] [Google Scholar]
  99. Meltzer H. Y., Fang V. S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry. 1976 Mar;33(3):279–286. doi: 10.1001/archpsyc.1976.01770030003001. [DOI] [PubMed] [Google Scholar]
  100. Meltzer H. Y., Goode D. J., Schyve P. M., Young M., Fang V. S. Effect of clozapine on human serum prolactin levels. Am J Psychiatry. 1979 Dec;136(12):1550–1555. doi: 10.1176/ajp.136.12.1550. [DOI] [PubMed] [Google Scholar]
  101. Meltzer H. Y., Piyakalmala S., Schyve P., Fang V. S. Lack of effect of tricyclic antidepressants on serum prolactin levels. Psychopharmacology (Berl) 1977 Jan 31;51(2):185–187. doi: 10.1007/BF00431738. [DOI] [PubMed] [Google Scholar]
  102. Mendels J. Lithium in the treatment of depression. Am J Psychiatry. 1976 Apr;133(4):373–378. doi: 10.1176/ajp.133.4.373. [DOI] [PubMed] [Google Scholar]
  103. Mendelson J. H., Ellingboe J., Keuhnle J. C., Mello N. K. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology. 1978 Oct;3(3-4):231–236. doi: 10.1016/0306-4530(78)90013-6. [DOI] [PubMed] [Google Scholar]
  104. Mendelson J. H., Kuehnle J., Ellingboe J., Babor T. F. Plasma testosterone levels before, during and after chronic marihuana smoking. N Engl J Med. 1974 Nov 14;291(20):1051–1055. doi: 10.1056/NEJM197411142912003. [DOI] [PubMed] [Google Scholar]
  105. Mendelson J. H., Mello N. K., Ellingboe J. Effects of acute alcohol intake on pituitary-gonadal hormones in normal human males. J Pharmacol Exp Ther. 1977 Sep;202(3):676–682. [PubMed] [Google Scholar]
  106. Mendelson J. H., Mendelson J. E., Patch V. D. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther. 1975 Jan;192(1):211–217. [PubMed] [Google Scholar]
  107. Murray M. A., Bancroft J. H., Anderson D. C., Tennent T. G., Carr P. J. Endocrine changes in male sexual deviants after treatment with anti-androgens, oestrogens or tranquillizers. J Endocrinol. 1975 Nov;67(2):179–188. doi: 10.1677/joe.0.0670179. [DOI] [PubMed] [Google Scholar]
  108. Müller E. E., Genazzani A. R., Murru S. Nomifensine: diagnostic test in hyperprolactinemic states. J Clin Endocrinol Metab. 1978 Dec;47(6):1352–1357. doi: 10.1210/jcem-47-6-1352. [DOI] [PubMed] [Google Scholar]
  109. Nakai Y., Imura H., Yoshimi T., Matsukura S. Adrenergic control mechanism for ACTH secretion in man. Acta Endocrinol (Copenh) 1973 Oct;74(2):263–270. doi: 10.1530/acta.0.0740263. [DOI] [PubMed] [Google Scholar]
  110. Nasrallah H. A., Freed W. J., Rogol A., Wyatt R. J. Propranolol and prolactin. Lancet. 1977 Dec 3;2(8049):1175–1176. doi: 10.1016/s0140-6736(77)91563-x. [DOI] [PubMed] [Google Scholar]
  111. Noel G. L., Suh H. K., Stone J. G., Frantz A. G. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab. 1972 Dec;35(6):840–851. doi: 10.1210/jcem-35-6-840. [DOI] [PubMed] [Google Scholar]
  112. Padfield P. L., Park S. J., Morton J. J., Braidwood A. E. Plasma levels of antidiuretic hormone in patients receiving prolonged lithium therapy. Br J Psychiatry. 1977 Feb;130:144–147. doi: 10.1192/bjp.130.2.144. [DOI] [PubMed] [Google Scholar]
  113. Pandey G. N., Garver D. L., Tamminga C., Ericksen S., Ali S. I., Davis J. M. Postsynaptic supersensitivity in schizophrenia. Am J Psychiatry. 1977 May;134(5):518–522. doi: 10.1176/ajp.134.5.518. [DOI] [PubMed] [Google Scholar]
  114. Parkes J. D., Debono A. G., Jenner P., Walters J. Amphetamines, growth hormone and narcolepsy. Br J Clin Pharmacol. 1977 Jun;4(3):343–349. doi: 10.1111/j.1365-2125.1977.tb00722.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Parkes J. D., Debono A. G., Marsden C. D. Letter: Growth-hormone responses in Parkinson's disease. Lancet. 1976 Feb 28;1(7957):483–484. doi: 10.1016/s0140-6736(76)91505-1. [DOI] [PubMed] [Google Scholar]
  116. Persky H., O'Brien C. P., Fine E., Howard W. J., Khan M. A., Beck R. W. The effect of alcohol and smoking on testosterone function and aggression in chronic alcoholics. Am J Psychiatry. 1977 Jun;134(6):621–625. doi: 10.1176/ajp.134.6.621. [DOI] [PubMed] [Google Scholar]
  117. Persson T., Roos B. E. 5-hydroxytryptophan for depression. Lancet. 1967 Nov 4;2(7523):987–988. doi: 10.1016/s0140-6736(67)90824-0. [DOI] [PubMed] [Google Scholar]
  118. Plant T. M., Nakai Y., Belchetz P., Keogh E., Knobil E. The sites of action of estradiol and phentolamine in the inhibition of the pulsatile, circhoral discharges of LH in the rhesus monkey (Macaca mulatta). Endocrinology. 1978 Apr;102(4):1015–1018. doi: 10.1210/endo-102-4-1015. [DOI] [PubMed] [Google Scholar]
  119. Post R. M. Cocaine psychoses: a continuum model. Am J Psychiatry. 1975 Mar;132(3):225–231. doi: 10.1176/ajp.132.3.225. [DOI] [PubMed] [Google Scholar]
  120. Prange A. J., Jr, Lara P. P., Wilson I. C., Alltop L. B., Breese G. R. Effects of thyrotropin-releasing hormone in depression. Lancet. 1972 Nov 11;2(7785):999–1002. doi: 10.1016/s0140-6736(72)92407-5. [DOI] [PubMed] [Google Scholar]
  121. Ravitz A. J., Moore K. E. Effects of amphetamine, methylphenidate and cocaine on serum prolactin concentrations in the male rat. Life Sci. 1977 Jul 15;21(2):267–272. doi: 10.1016/0024-3205(77)90311-3. [DOI] [PubMed] [Google Scholar]
  122. Rees L., Butler P. W., Gosling C., Besser G. M. Adrenergic blockade and the corticosteroid and growth hormone responses to methylamphetamine. Nature. 1970 Nov 7;228(5271):565–566. doi: 10.1038/228565a0. [DOI] [PubMed] [Google Scholar]
  123. Ridges A. P., Lawton K., Harper P., Ghosh C., Hindson N. Propranolol in schizophrenia. Lancet. 1977 Nov 5;2(8045):986–986. doi: 10.1016/s0140-6736(77)90939-4. [DOI] [PubMed] [Google Scholar]
  124. Rivera J. L., Lal S., Ettigi P., Hontela S., Muller H. F., Friesen H. G. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976 May;5(3):273–282. doi: 10.1111/j.1365-2265.1976.tb01953.x. [DOI] [PubMed] [Google Scholar]
  125. Rotrosen J., Angrist B., Gershon S., Paquin J., Branchey L., Oleshansky M., Halpern F., Sachar E. J. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research. Br J Psychiatry. 1979 Nov;135:444–456. doi: 10.1192/bjp.135.5.444. [DOI] [PubMed] [Google Scholar]
  126. Rubin P., Swezey S., Blaschke T. Naloxone lowers plasma-prolactin in man. Lancet. 1979 Jun 16;1(8129):1293–1293. doi: 10.1016/s0140-6736(79)92248-7. [DOI] [PubMed] [Google Scholar]
  127. Saldanha V. F., Havard C. W., Bird R., Gardner R. The effect of chlorpromazine on pituitary function. Clin Endocrinol (Oxf) 1972 Apr;1(2):173–180. doi: 10.1111/j.1365-2265.1972.tb00388.x. [DOI] [PubMed] [Google Scholar]
  128. Scanlon M. F., Gomez-Pan A., Mora B., Cook D. B., Dewar J. H., Hildyard A., Weightman D. R., Evered D. C., Hall R. Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man. Br J Clin Pharmacol. 1977;4(Suppl 2):191S–197S. doi: 10.1111/j.1365-2125.1977.tb05752.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Scanlon M. F., Smith B. R., Hall R. Thyroid-stimulating hormone: neuroregulation and clinical applications. Part 2. Clin Sci Mol Med. 1978 Aug;55(2):129–138. doi: 10.1042/cs0550129. [DOI] [PubMed] [Google Scholar]
  130. Schaefer C. F., Gunn C. G., Dubowski K. M. Letter: Normal plasma testosterone concentrations after marihuana smoking. N Engl J Med. 1975 Apr 17;292(16):867–868. doi: 10.1056/nejm197504172921615. [DOI] [PubMed] [Google Scholar]
  131. Schildkraut J. J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965 Nov;122(5):509–522. doi: 10.1176/ajp.122.5.509. [DOI] [PubMed] [Google Scholar]
  132. Schwinn G., Schwarck H., McIntosh C., Milstrey H. R., Willms B., Köbberling J. Effect of the dopamine receptor blocking agent pimozide on the growth hormone response to arginine and exercise and on the spontaneous growth hormone fluctuations. J Clin Endocrinol Metab. 1976 Nov;43(5):1183–1185. doi: 10.1210/jcem-43-5-1183. [DOI] [PubMed] [Google Scholar]
  133. Shaar C. J., Frederickson R. C., Dininger N. B., Jackson L. Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin--evidence for regulation by an endogenous opioid peptide in brain. Life Sci. 1977 Sep 15;21(6):853–860. doi: 10.1016/0024-3205(77)90415-5. [DOI] [PubMed] [Google Scholar]
  134. Shaw K. M., Lees A. J., Hayes S., Ross E. J., Stern G. M., Thompson B. D. Letter: Growth-hormone response to bromocriptine in parkinsonism. Lancet. 1976 Jan 24;1(7952):194–194. doi: 10.1016/s0140-6736(76)91298-8. [DOI] [PubMed] [Google Scholar]
  135. Sherman L., Kim S., Benjamin F., Kolodny H. D. Effect of chlorpromazine on serum growth-hormone concentration in man. N Engl J Med. 1971 Jan 14;284(2):72–74. doi: 10.1056/NEJM197101142840203. [DOI] [PubMed] [Google Scholar]
  136. Singer I., Rotenberg D., Puschett J. B. Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies. J Clin Invest. 1972 May;51(5):1081–1091. doi: 10.1172/JCI106900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Slater S., de La Vega C. E., Skyler J., Murphy D. L. Plasma prolactin stimulation by fenfluramine and amphetamine. Psychopharmacol Bull. 1976 Oct;12(4):26–27. [PubMed] [Google Scholar]
  138. Snyder S. H., Enna S. J., Young A. B. Brain mechanisms associated with therapeutic actions of benzodiazepines: focus on neurotransmitters. Am J Psychiatry. 1977 Jun;134(6):662–665. doi: 10.1176/ajp.134.6.662. [DOI] [PubMed] [Google Scholar]
  139. Strain G. W., Strain J. J. Endocrine functioning and psychological disorders. Psychosom Med. 1978 Feb;40(1):2–3. doi: 10.1097/00006842-197802000-00002. [DOI] [PubMed] [Google Scholar]
  140. Strauch G., Valcke J. C., Mahoudeau J. A., Bricaire H. Hormonal changes induced by bromocriptine (CB-154) at the early stage of treatment. J Clin Endocrinol Metab. 1977 Mar;44(3):588–590. doi: 10.1210/jcem-44-3-588. [DOI] [PubMed] [Google Scholar]
  141. Stubbs W. A., Delitala G., Jones A., Jeffcoate W. J., Edwards C. R., Ratter S. J., Besser G. M., Bloom S. R., Alberti K. G. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet. 1978 Dec 9;2(8102):1225–1227. doi: 10.1016/s0140-6736(78)92100-1. [DOI] [PubMed] [Google Scholar]
  142. Syvälahti E. K., Kanto J. H. Serum growth hormone, serum immunoreactive insulin and blood glucose response to oral and intravenous diazepam in man. Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):74–82. [PubMed] [Google Scholar]
  143. Thorner M. O., Chait A., Aitken M., Benker G., Bloom S. R., Mortimer C. H., Sanders P., Mason A. S., Besser G. M. Bromocriptine treatment of acromegaly. Br Med J. 1975 Feb 8;1(5953):299–303. doi: 10.1136/bmj.1.5953.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Thorner M. O., Ryan S. M., Wass J. A., Jones A., Bouloux P., Williams S., Besser G. M. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab. 1978 Aug;47(2):372–378. doi: 10.1210/jcem-47-2-372. [DOI] [PubMed] [Google Scholar]
  145. Tolis G., Hickey J., Guyda H. Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab. 1975 Oct;41(4):797–800. doi: 10.1210/jcem-41-4-797. [DOI] [PubMed] [Google Scholar]
  146. Van Thiel D. H., Lester R., Vaitukaitis J. Evidence for a defect in pituitary secretion of luteinizing hormone in chronic alcoholic men. J Clin Endocrinol Metab. 1978 Sep;47(3):499–507. doi: 10.1210/jcem-47-3-499. [DOI] [PubMed] [Google Scholar]
  147. Weick R. F. Acute effects of adrenergic receptor blocking drugs and neuroleptic agents on pulsatile discharges of luteinizing hormone in the ovariectomized rat. Neuroendocrinology. 1978;26(2):108–117. doi: 10.1159/000122774. [DOI] [PubMed] [Google Scholar]
  148. Weiner R. I., Ganong W. F. Role of brain monoamines and histamine in regulation of anterior pituitary secretion. Physiol Rev. 1978 Oct;58(4):905–976. doi: 10.1152/physrev.1978.58.4.905. [DOI] [PubMed] [Google Scholar]
  149. Wells B., Silverstone T., Rees L. The effect of oral dextroamphetamine on prolactin secretion in man. Neuropharmacology. 1978 Dec;17(12):1060–1061. doi: 10.1016/0028-3908(78)90037-0. [DOI] [PubMed] [Google Scholar]
  150. Widerlöv E., Wide L., Sjöström R. Effects of tricyclic antidepressants on human plasma levels of TSH, GH and prolactin. Acta Psychiatr Scand. 1978 Nov;58(5):449–456. doi: 10.1111/j.1600-0447.1978.tb03575.x. [DOI] [PubMed] [Google Scholar]
  151. Willoughby J. O., Brazeau P., Martin J. B. Pulsatile growth hormone and prolactin: effects of (+) butaclamol, a dopamine receptor blocking agent. Endocrinology. 1977 Oct;101(4):1298–1303. doi: 10.1210/endo-101-4-1298. [DOI] [PubMed] [Google Scholar]
  152. Wilson R. G., Hamilton J. R., Boyd W. D., Forrest A. P., Cole E. N., Boyns A. R., Griffiths K. The effect of long term phenothiazine therapy on plasma prolactin. Br J Psychiatry. 1975 Jul;127:71–74. doi: 10.1192/bjp.127.1.71. [DOI] [PubMed] [Google Scholar]
  153. Wright J. W., Fry D. E., Merry J., Marks V. Abnormal hypothalamic-pituitary-gonadal function in chronic alcoholics. Br J Addict Alcohol Other Drugs. 1976 Sep;71(3):211–215. doi: 10.1111/j.1360-0443.1976.tb00083.x. [DOI] [PubMed] [Google Scholar]
  154. Yorkston N. J., Zaki S. A., Pitcher D. R., Gruzelier J. H., Hollander D., Sergeant H. G. Propranolol as an adjunct to the treatment of schizophrenia. Lancet. 1977 Sep 17;2(8038):575–578. doi: 10.1016/s0140-6736(77)91427-1. [DOI] [PubMed] [Google Scholar]
  155. von Knorring L., Oreland L., Perris C. Neurophysiological measures and visual averaged evoked responses in psychiatric patients. Relationship to monoamine oxidase activity in platelets. Neuropsychobiology. 1977;3(2-3):65–74. doi: 10.1159/000117592. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES